Thursday, November 6, 2025
Thomas Meier to take over as CEO of Medios AG in February 2026, leading the company into its next phase of growth
The Supervisory Board of Medios AG has appointed Thomas Meier as a member of the Executive Board effective February 1, 2026, and designated him as the company’s new Chief Executive Officer (CEO). He succeeds Matthias Gaertner, who will remain in office until December 31, 2025.
Thomas Meier brings extensive international leadership experience in the pharmaceutical industry. Since 2020, he has served as CEO of the Swiss Bachem Holding AG, a publicly listed CDMO (Contract Development and Manufacturing Organization). Prior to that, he held the position of Chief Operations Officer at Bachem and led manufacturing at Peninsula Laboratories in San Carlos, California (USA), from 2001 to 2004.
With Thomas Meier, Medios gains an experienced leader with a strong record of capital-efficient, profitable growth. He is expected to play a key role in driving the further expansion of the Medios Group.
Dr. Yann Samson, Chairman of the Supervisory Board of Medios AG, stated:“With Thomas Meier, we are gaining an internationally experienced leader with a strong track record of capital-efficient, profitable growth. We warmly welcome him and are convinced that his entrepreneurial mindset, expertise, and leadership will significantly contribute to achieving our ambitious goals and sustainably enhancing value for our shareholders, partners, and customers.”
At the same time, the Supervisory Board expressed its sincere gratitude to Matthias Gaertner for his outstanding work and great commitment over the past ten years, during which he played a decisive role in shaping the growth and success of Medios AG.
Thomas Meier commented: “I am very much looking forward to the task of leading Medios into its next phase of development. Together with my colleagues on the Executive Board and the entire Medios team, I will continue to consistently develop the successful strategy and sustainably expand Medios’ position in the European Specialty Pharma market.”
Related articles
Dr. Johanna Graf becomes Deputy Chair of BEYOND FLUORID
Renowned dentist and author Dr. Johanna Graf becomes Deputy Chair of the Scientific Advisory Board at BEYOND FLUORID, reinforcing the initiative’s scientific independence.
Dr. Romy Ermler becomes new President of the German Dental Association
The Federal Assembly of the German Dental Association has elected Dr. Romy Ermler as its new President. Together with Dr. Ralf Hausweiler and Dr. Doris Seiz, she will lead the new Executive Board.
Philipp Brunner becomes CFO of Plan.Net Group
Effective November 1, Philipp Brunner joins Plan.Net Group as the new CFO, succeeding Dr. Ingo Stein. He will oversee all financial operations and strengthen the group’s digital finance strategy.
Two new leaders join Chiesi’s management team
Chiesi’s leadership team is growing: With Christine Contré and Sven Noffke, Chiesi gains two experienced professionals in Medical Affairs and Legal & Compliance.
Tomas Mihal appointed new Head of STADA Germany
STADA has appointed Tomas Mihal as its new Head of Germany and member of the global STADA Executive Committee. The experienced manager will further strengthen the company’s position and drive sustainable growth across all three business segments.
Adrian Haack joins WEFRA LIFE Management Board
Starting October 2025, Adrian Haack will join the WEFRA LIFE management board. With his international experience, he will drive the agency group’s growth, innovation, and AI transformation.
BeOne Medicines appoints Walter Hafian-Hatzenbichler as Director of Corporate Affairs Germany
BeOne Medicines has permanently appointed Walter Gerhard Hafian-Hatzenbichler as Director of Corporate Affairs Germany. He will oversee the company’s strategic communications and public affairs in Germany.
Kenneth Garcia Marques now leads Johnson & Johnson MedTech Germany
Johnson & Johnson MedTech Germany has appointed Kenneth Garcia Marques as its new Managing Director. With over 20 years of international experience, he brings fresh ideas and leadership to drive the future of MedTech in Germany.